UA93543C2 - Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон - Google Patents

Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон

Info

Publication number: UA93543C2
Authority: UA; Ukraine
Prior art keywords: dosage form; naloxone; form containing; containing oxycodone; amount
Prior art date: 2005-02-28

Application number

UAA200811581A

Other languages

English (en)

Ukrainian (uk)

Inventor

Петра Леендеккер

Михаэль Хопп

Кевин Смит

Original Assignee

Ebpo-Селтик C.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-28

Filing date

2006-02-28

Publication date

2011-02-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93543(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-28 Application filed by Ebpo-Селтик C.A. filed Critical Ebpo-Селтик C.A.

2011-02-25 Publication of UA93543C2 publication Critical patent/UA93543C2/ru

Links

239000002552 dosage form Substances 0.000 title abstract 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title 1
229960004127 naloxone Drugs 0.000 title 1
229960002085 oxycodone Drugs 0.000 title 1
BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 abstract 1
206010010774 Constipation Diseases 0.000 abstract 1
208000014540 Functional gastrointestinal disease Diseases 0.000 abstract 1
201000007637 bowel dysfunction Diseases 0.000 abstract 1
229960005250 naloxone hydrochloride Drugs 0.000 abstract 1
RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 abstract 1
229960003617 oxycodone hydrochloride Drugs 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

UAA200811581A 2005-02-28 2006-02-28 Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон UA93543C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05004377A EP1695700A1 (en)	2005-02-28	2005-02-28	Dosage form containing oxycodone and naloxone

Publications (1)

Publication Number	Publication Date
UA93543C2 true UA93543C2 (ru)	2011-02-25

Family

ID=34933990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200811581A UA93543C2 (ru)	2005-02-28	2006-02-28	Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон

Country Status (26)

Country	Link
US (5)	US20080145429A1 (ru)
EP (5)	EP1695700A1 (ru)
JP (2)	JP2008531650A (ru)
KR (1)	KR20070107805A (ru)
CN (2)	CN101128191A (ru)
AT (1)	ATE517611T1 (ru)
AU (2)	AU2006217870B2 (ru)
BR (1)	BRPI0607975A2 (ru)
CA (3)	CA2768075A1 (ru)
CY (1)	CY1111967T1 (ru)
DE (2)	DE202006020095U1 (ru)
DK (2)	DK1855657T3 (ru)
ES (1)	ES2370409T3 (ru)
FI (1)	FI7750U1 (ru)
HR (1)	HRP20110775T1 (ru)
IL (2)	IL185514A0 (ru)
ME (1)	ME01262B (ru)
MX (1)	MX2007010494A (ru)
NZ (1)	NZ588875A (ru)
PL (1)	PL1855657T3 (ru)
PT (1)	PT1855657E (ru)
RS (1)	RS51984B (ru)
RU (1)	RU2428985C2 (ru)
SI (1)	SI1855657T1 (ru)
UA (1)	UA93543C2 (ru)
WO (1)	WO2006089973A2 (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja)	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
CN1525851A (zh)	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
ES2654819T3 (es)	2001-10-18	2018-02-15	Nektar Therapeutics	Conjugados poliméricos de antagonistas de opioides
EP1492505B1 (en)	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmaceutical preparation containing oxycodone and naloxone
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1604667A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
CA2594373A1 (en) *	2005-01-28	2006-08-03	Euro-Celtique S.A.	Alcohol resistant dosage forms
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
EP1695700A1 (en)	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
DE202006018609U1 (de) *	2006-08-29	2007-05-16	Euro-Celtique S.A.	Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
AU2007317788B2 (en) *	2006-11-07	2013-05-02	Nektar Therapeutics	Dosage forms and co-administration of an opioid agonist and an opioid antagonist
US20090004231A1 (en)	2007-06-30	2009-01-01	Popp Shane M	Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) *	2007-09-26	2009-04-01	Euro-Celtique S.A.	Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
US8486448B2 (en)	2007-12-17	2013-07-16	Paladin Labs Inc.	Misuse preventative, controlled release formulation
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
AU2009243681B2 (en)	2008-05-09	2013-12-19	Grunenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
RU2478388C2 (ru) *	2008-07-07	2013-04-10	Еуро-Селтик С.А.	Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
ES2509497T3 (es)	2008-12-16	2014-10-17	Paladin Labs Inc.	Formulación de liberación controlada para evitar un uso indebido
MY152279A (en) *	2009-03-10	2014-09-15	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
KR101738369B1 (ko)	2009-07-22	2017-05-22	그뤼넨탈 게엠베하	핫 멜트 압출된 제어 방출 투여형
CN102639118B (zh)	2009-07-22	2015-07-29	格吕伦塔尔有限公司	氧化稳定的抗干扰剂型
US8475832B2 (en)	2009-08-07	2013-07-02	Rb Pharmaceuticals Limited	Sublingual and buccal film compositions
ES2606227T3 (es)	2010-02-03	2017-03-23	Grünenthal GmbH	Preparación de una composición farmacéutica en polvo mediante una extrusora
US9700508B2 (en)	2010-05-10	2017-07-11	Euro-Celtique S.A.	Pharmaceutical compositions comprising hydromorphone and naloxone
EP2568965A1 (en)	2010-05-10	2013-03-20	Euro-Celtique S.A.	Combination of active loaded granules with additional actives
PH12012502083A1 (en)	2010-05-10	2017-07-26	Euro Celtique Sa	Manufacturing of active-free granules and tablets comprising the same
CN103118668B (zh) *	2010-08-13	2016-07-06	欧洲凯尔特公司	黏结剂在制备贮藏稳定的制剂中的用途
TWI516286B (zh)	2010-09-02	2016-01-11	歌林達股份有限公司	含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo sal inorgânico
EP2658523A1 (en) *	2010-12-28	2013-11-06	Euro-Celtique S.A.	A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
BR112014001091A2 (pt)	2011-07-29	2017-02-14	Gruenenthal Gmbh	comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru)	2011-07-29	2014-06-30	Грюненталь Гмбх	Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
KR102082529B1 (ko)	2012-04-17	2020-02-27	퍼듀 퍼머 엘피	오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
EP2838512B1 (en)	2012-04-18	2018-08-22	Grünenthal GmbH	Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en)	2013-05-29	2017-08-22	Grünenthal GmbH	Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en)	2013-05-29	2016-04-13	Grünenthal GmbH	Tamper-resistant dosage form containing one or more particles
BR112016000194A8 (pt)	2013-07-12	2019-12-31	Gruenenthal Gmbh	forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
US10071089B2 (en)	2013-07-23	2018-09-11	Euro-Celtique S.A.	Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015071380A1 (en)	2013-11-13	2015-05-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3073994A1 (en)	2013-11-26	2016-10-05	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of cryo-milling
CA2875384A1 (en)	2013-12-20	2015-06-20	AntiOP, Inc.	Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en)	2014-03-14	2017-02-07	Adapt Pharma Limited	Nasal drug products and methods of their use
MX365383B (es)	2014-03-14	2019-05-31	Opiant Pharmaceuticals Inc	Medicamentos de administracion nasal y metodos para su uso.
US10085937B2 (en)	2014-03-14	2018-10-02	Adapt Pharma Limited	Nasal drug products and methods of their use
US9480644B2 (en)	2014-03-14	2016-11-01	Opiant Pharmaceuticals, Inc.	Nasal drug products and methods of their use
WO2015173195A1 (en)	2014-05-12	2015-11-19	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru)	2014-05-26	2017-05-31	Грюненталь Гмбх	Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EP3174534A1 (en) *	2014-08-01	2017-06-07	KRKA, d.d., Novo mesto	Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en)	2014-10-17	2017-12-26	Purdue Pharma L.P.	Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256451A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Dosage of naloxone
US20160256453A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
WO2016170097A1 (en)	2015-04-24	2016-10-27	Grünenthal GmbH	Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2016193456A2 (en) *	2015-06-03	2016-12-08	Develco Pharma Schweiz Ag	Opioid receptor antagonist for use in treating patients with severe constipation
JP2018526414A (ja)	2015-09-10	2018-09-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en)	2015-10-07	2018-04-17	Banner Life Sciences Llc	Opioid abuse deterrent dosage forms
US10335405B1 (en)	2016-05-04	2019-07-02	Patheon Softgels, Inc.	Non-burst releasing pharmaceutical composition
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
JP2020526500A (ja)	2017-06-30	2020-08-31	パーデュー、ファーマ、リミテッド、パートナーシップ	治療方法及びその剤形
US12475984B2 (en) *	2019-08-05	2025-11-18	Rxassurance Corporation	Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) *	2022-03-11	2024-04-25	John Abernethy	Opioid overdose reversal mixtures

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3173876A (en) *	1960-05-27	1965-03-16	John C Zobrist	Cleaning methods and compositions
NL271831A (ru) *	1960-11-29
US3276586A (en) *	1963-08-30	1966-10-04	Rosaen Filter Co	Indicating means for fluid filters
NL6714885A (ru) *	1967-11-02	1969-05-06
US3541006A (en) *	1968-07-03	1970-11-17	Amicon Corp	Ultrafiltration process
US3773955A (en)	1970-08-03	1973-11-20	Bristol Myers Co	Analgetic compositions
FR2183546B1 (ru) *	1972-05-10	1975-06-20	Servier Lab
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) *	1973-09-28	1975-11-04	Sandoz Ag	Patient ventilator apparatus
US3966940A (en) *	1973-11-09	1976-06-29	Bristol-Myers Company	Analgetic compositions
GB1478759A (en) *	1974-11-18	1977-07-06	Alza Corp	Process for forming outlet passageways in pills using a laser
US3966040A (en) *	1975-03-05	1976-06-29	Hazelwood John E	Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) *	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4126684A (en) *	1976-02-11	1978-11-21	Ciba-Geigy Corporation	4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) *	1976-02-23	1977-12-13	Coherent Radiation	Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) *	1978-10-23	1981-08-25	Alza Corporation	Process for manufacturing device with dispersion zone
US4200098A (en) *	1978-10-23	1980-04-29	Alza Corporation	Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en)	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
GB8332556D0 (en)	1983-12-06	1984-01-11	Reckitt & Colmann Prod Ltd	Analgesic compositions
US4668685A (en) *	1984-07-05	1987-05-26	E.I. Du Pont De Nemours And Company	Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) *	1986-07-18	1989-08-29	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
DE3812567A1 (de) *	1988-04-15	1989-10-26	Basf Ag	Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en)	1988-07-29	1990-01-31	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) *	1988-11-01	1993-08-17	Alza Corporation	Abusable substance dosage form having reduced abuse potential
US5656295A (en) *	1991-11-27	1997-08-12	Euro-Celtique, S.A.	Controlled release oxycodone compositions
US5266331A (en) *	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5273760A (en) *	1991-12-24	1993-12-28	Euroceltigue, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) *	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5286493A (en) *	1992-01-27	1994-02-15	Euroceltique, S.A.	Stabilized controlled release formulations having acrylic polymer coating
US5681585A (en) *	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5324351A (en) *	1992-08-13	1994-06-28	Euroceltique	Aqueous dispersions of zein and preparation thereof
NZ260408A (en) *	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) *	1993-07-29	2004-03-04	Zenz, Michael, Prof. Dr.med.	Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) *	1994-05-25	1995-05-02	Euro-Celtique, S.A.	Powder-layered morphine sulfate formulations
US5866154A (en) *	1994-10-07	1999-02-02	The Dupont Merck Pharmaceutical Company	Stabilized naloxone formulations
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US5865161A (en) *	1995-01-04	1999-02-02	Bruce; Norman R.	Baseball pitching device
US20020006964A1 (en) *	1995-05-16	2002-01-17	Young James W.	Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de)	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) *	1997-04-14	2001-03-27	Janssen Pharmaceutica N.V.	Compositions containing an antifungal and a cationic agent
PT1009387E (pt) *	1997-07-02	2006-08-31	Euro Celtique Sa	Formulacoes estabilizadas de libertacao controlada de tramadol
JP2001526228A (ja) *	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
CA2314896C (en) *	1997-12-22	2005-09-13	Euro-Celtique, S.A.	A method of preventing abuse of opioid dosage forms
SK13312000A3 (sk) *	1998-03-27	2001-05-10	Pharmacia And Upjohn Company	Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
US20030178031A1 (en) *	1999-05-07	2003-09-25	Du Pen, Inc.	Method for cancer pain treatment
CA2376277C (en) *	1999-06-11	2011-03-15	Telstra New Wave Pty Ltd	A method of developing an interactive system
US20030118641A1 (en) *	2000-07-27	2003-06-26	Roxane Laboratories, Inc.	Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) *	1999-08-19	2001-02-22	Boehringer Ingelheim Pharma	Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en)	1999-09-17	2001-07-10	James S. Factor	Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6716449B2 (en) *	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) *	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
US7223421B2 (en) *	2000-06-30	2007-05-29	Mcneil-Ppc, Inc.	Teste masked pharmaceutical particles
AR031152A1 (es) *	2000-10-31	2003-09-10	Upjohn Co	Tratamientos nuevos para el sindrome de piernas inquietas
BR0208922A (pt) *	2001-04-19	2004-04-20	Warner Lambert Co	Aminoácidos bicìclicos ou tricìclicos fundidos
UA81224C2 (ru) *	2001-05-02	2007-12-25	Euro Celtic S A	Дозированная форма оксикодона и ее применение
CN1525851A (zh) *	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
JP2005515960A (ja) *	2001-05-11	2005-06-02	エンドーファーマシューティカルズ，インコーポレイティド	乱用耐性のオピオイド投薬形態
SI1416842T1 (sl) *	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) *	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) *	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
ATE431738T1 (de) *	2001-08-06	2009-06-15	Euro Celtique Sa	Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
CA2456322A1 (en) *	2001-08-06	2003-02-20	Euro-Celtique, S.A.	Compositions and methods to prevent abuse of opioids
JP2005512965A (ja) *	2001-09-24	2005-05-12	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
AU2003209461A1 (en)	2002-03-06	2003-09-16	Euro-Celtique S.A.	Analog scale for measuring pain
EP1492505B1 (en) *	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) *	2002-04-09	2003-10-09	Barry Sherman	Opioid antagonist compositions and dosage forms
US7399488B2 (en) *	2002-07-05	2008-07-15	Collegium Pharmaceutical, Inc.	Abuse-deterrent pharmaceutical compositions of opiods and other drugs
MY135852A (en) *	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
US7700626B2 (en) *	2004-06-04	2010-04-20	Adolor Corporation	Compositions containing opioid antagonists
EP1604666A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone

2005
- 2005-02-28 EP EP05004377A patent/EP1695700A1/en not_active Withdrawn
2006
- 2006-02-28 CA CA2768075A patent/CA2768075A1/en not_active Abandoned
- 2006-02-28 ME MEP-2011-173A patent/ME01262B/me unknown
- 2006-02-28 MX MX2007010494A patent/MX2007010494A/es active IP Right Grant
- 2006-02-28 AU AU2006217870A patent/AU2006217870B2/en not_active Expired
- 2006-02-28 RU RU2007135991/15A patent/RU2428985C2/ru not_active IP Right Cessation
- 2006-02-28 ES ES06708567T patent/ES2370409T3/es not_active Expired - Lifetime
- 2006-02-28 CA CA2960011A patent/CA2960011A1/en not_active Abandoned
- 2006-02-28 EP EP06708567A patent/EP1855657B1/en not_active Revoked
- 2006-02-28 CN CNA2006800059691A patent/CN101128191A/zh not_active Withdrawn
- 2006-02-28 SI SI200631121T patent/SI1855657T1/sl unknown
- 2006-02-28 EP EP19167974.5A patent/EP3578173B1/en not_active Expired - Lifetime
- 2006-02-28 HR HR20110775T patent/HRP20110775T1/hr unknown
- 2006-02-28 RS RS20110458A patent/RS51984B/sr unknown
- 2006-02-28 PL PL06708567T patent/PL1855657T3/pl unknown
- 2006-02-28 JP JP2007557493A patent/JP2008531650A/ja not_active Withdrawn
- 2006-02-28 NZ NZ588875A patent/NZ588875A/en not_active IP Right Cessation
- 2006-02-28 PT PT06708567T patent/PT1855657E/pt unknown
- 2006-02-28 CA CA2599156A patent/CA2599156C/en not_active Expired - Lifetime
- 2006-02-28 DE DE202006020095U patent/DE202006020095U1/de not_active Expired - Lifetime
- 2006-02-28 DK DK06708567.0T patent/DK1855657T3/da active
- 2006-02-28 US US11/885,288 patent/US20080145429A1/en not_active Abandoned
- 2006-02-28 EP EP10176716A patent/EP2258353A3/en not_active Withdrawn
- 2006-02-28 BR BRPI0607975-0A patent/BRPI0607975A2/pt not_active Application Discontinuation
- 2006-02-28 CN CN201410239260.4A patent/CN104027297A/zh active Pending
- 2006-02-28 DE DE19167974.5T patent/DE19167974T1/de active Pending
- 2006-02-28 KR KR1020077022380A patent/KR20070107805A/ko not_active Ceased
- 2006-02-28 UA UAA200811581A patent/UA93543C2/ru unknown
- 2006-02-28 EP EP15180143.8A patent/EP2962686B1/en not_active Revoked
- 2006-02-28 WO PCT/EP2006/060341 patent/WO2006089973A2/en not_active Ceased
- 2006-02-28 AT AT06708567T patent/ATE517611T1/de active
2007
- 2007-04-13 FI FI20070153U patent/FI7750U1/fi not_active IP Right Cessation
- 2007-08-26 IL IL185514A patent/IL185514A0/en unknown
- 2007-09-27 DK DK200700248U patent/DK200700248U3/da not_active IP Right Cessation
2009
- 2009-01-15 IL IL196539A patent/IL196539A0/en unknown
- 2009-03-13 AU AU2009201019A patent/AU2009201019B2/en not_active Ceased
2010
- 2010-11-12 US US12/945,164 patent/US20110172259A1/en not_active Abandoned
2011
- 2011-10-25 CY CY20111101011T patent/CY1111967T1/el unknown
- 2011-12-16 US US13/329,218 patent/US20120225901A1/en not_active Abandoned
2013
- 2013-10-02 US US14/044,175 patent/US20140031382A1/en not_active Abandoned
2014
- 2014-04-24 JP JP2014090036A patent/JP6235962B2/ja not_active Expired - Lifetime
2017
- 2017-03-23 US US15/467,877 patent/US20180008593A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140031382A1 (en)	2014-01-30
SI1855657T1 (sl)	2011-11-30
EP1855657A2 (en)	2007-11-21
ME01262B (me)	2013-06-20
EP3578173B1 (en)	2022-10-26
JP2014169303A (ja)	2014-09-18
RS51984B (sr)	2012-02-29
HK1111604A1 (en)	2008-08-15
DK1855657T3 (da)	2011-10-17
RU2007135991A (ru)	2009-04-10
US20080145429A1 (en)	2008-06-19
HRP20110775T1 (hr)	2011-11-30
IL196539A0 (en)	2011-07-31
KR20070107805A (ko)	2007-11-07
JP2008531650A (ja)	2008-08-14
AU2006217870B2 (en)	2008-12-18
CA2599156C (en)	2012-05-01
IL185514A0 (en)	2008-01-06
EP2258353A2 (en)	2010-12-08
JP6235962B2 (ja)	2017-11-22
EP3578173A1 (en)	2019-12-11
PL1855657T3 (pl)	2012-03-30
MX2007010494A (es)	2008-01-16
RU2428985C2 (ru)	2011-09-20
CA2960011A1 (en)	2006-08-31
DE202006020095U1 (de)	2007-11-08
EP1855657B1 (en)	2011-07-27
EP1695700A1 (en)	2006-08-30
CA2768075A1 (en)	2006-08-31
BRPI0607975A2 (pt)	2009-10-27
US20110172259A1 (en)	2011-07-14
FI7750U1 (fi)	2008-01-22
PT1855657E (pt)	2011-10-31
CY1111967T1 (el)	2015-11-04
WO2006089973A2 (en)	2006-08-31
AU2006217870A1 (en)	2006-08-31
EP2258353A3 (en)	2012-05-09
DE19167974T1 (de)	2021-12-30
CN104027297A (zh)	2014-09-10
WO2006089973A3 (en)	2006-12-28
ES2370409T3 (es)	2011-12-15
CA2599156A1 (en)	2006-08-31
NZ588875A (en)	2012-02-24
EP2962686B1 (en)	2019-04-10
DK200700248U1 (da)	2007-12-14
AU2009201019B2 (en)	2011-05-26
DK200700248U3 (da)	2008-02-08
CN101128191A (zh)	2008-02-20
ATE517611T1 (de)	2011-08-15
AU2009201019A1 (en)	2009-04-02
EP2962686A1 (en)	2016-01-06
FIU20070153U0 (fi)	2007-04-13
US20180008593A1 (en)	2018-01-11
US20120225901A1 (en)	2012-09-06

Publication	Publication Date	Title
UA93543C2 (ru)	2011-02-25	Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
TWI365880B (en)	2012-06-11	Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2007053698A3 (en)	2007-06-28	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PT2101740E (pt)	2013-12-23	Nova composição farmacêutica não susceptível de abuso que compreende opióides
MY157715A (en)	2016-07-15	Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
EA200870449A1 (ru)	2009-04-28	Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
PH12016501342A1 (en)	2018-06-11	Intranasal pharmaceutical dosage forms comprising naloxone
ZA200701167B (en)	2010-08-25	Compositions for delivering highly water soluble drugs
NZ589733A (en)	2012-07-27	Oral administration of peripherally-acting opioid antagonists
SG158168A1 (en)	2010-01-29	5ht2c receptor modulator compositions and methods of use
WO2005102389A3 (en)	2006-08-17	Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
TW200727922A (en)	2007-08-01	Solid dosage formulations of narcotic drugs having improved buccal adsorption
CO6341547A2 (es)	2011-11-21	Uso de antagonistas opioides para el tratamiento de retencion urinaria
MY154591A (en)	2015-06-30	Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ719087A (en)	2017-12-22	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
IL179896A (en)	2013-07-31	Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
HRP20100373T4 (hr)	2016-12-16	Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
UA83152C2 (ru)	2008-06-10	Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
TW200734334A (en)	2007-09-16	Treatment of substance abuse
SI2001456T1 (sl)	2010-04-30	Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
TW200833338A (en)	2008-08-16	Compounds for the treatment of sexual dysfunction
TW200505504A (en)	2005-02-16	Saquinavir mesylate oral dosage form
EP1849460A3 (en)	2007-11-14	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
ZA200804734B (en)	2009-11-25	Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
SI1589014T1 (sl)	2008-02-29	Postopek za pripravo derivatov 1,3-dihidro-2h-3-benzazepin-2-ona in uporaba za pripravo ivabradina in farmacevtsko sprejemljivih kislinskih adicijskih soli